Zoetis (ZTS) Expected to Announce Earnings on Thursday

Zoetis (NYSE:ZTS) is projected to release its earnings data before the market opens on Thursday, February 13th. Analysts expect Zoetis to post earnings of $1.37 per share and revenue of $2.31 billion for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Zoetis Price Performance

Shares of ZTS opened at $174.47 on Wednesday. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The company’s fifty day simple moving average is $169.16 and its 200 day simple moving average is $179.15. Zoetis has a 1-year low of $144.80 and a 1-year high of $200.53. The company has a market cap of $78.71 billion, a price-to-earnings ratio of 32.80, a PEG ratio of 2.77 and a beta of 0.90.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.15%. Zoetis’s dividend payout ratio is presently 37.59%.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Stifel Nicolaus cut their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Piper Sandler cut their price objective on Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research report on Monday. Morgan Stanley decreased their target price on Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Leerink Partners began coverage on Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target for the company. Finally, Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $214.00.

Insider Buying and Selling

In other news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is owned by insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.